| Effects of the AMPA antagonist ZK 200775 on visual function: a randomized controlled trial. | |
| | |
MedLine Citation:
|
PMID: 20711429 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: ZK 200775 is an antagonist at the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and had earned attention as a possible neuroprotective agent in cerebral ischemia. Probands receiving the agent within phase I trials reported on an alteration of visual perception. In this trial, the effects of ZK 200775 on the visual system were analyzed in detail. METHODOLOGY: In a randomised controlled trial we examined eyes and vision before and after the intravenous administration of two different doses of ZK 200775 and placebo. There were 3 groups of 6 probands each: Group 1 recieved 0.03 mg/kg/h, group 2 0.75 mg/kg/h of ZK 200775, the control group received 0.9% sodium chloride solution. Probands were healthy males aged between 57 and 69 years. The following methods were applied: clinical examination, visual acuity, ophthalmoscopy, colour vision, rod absolute threshold, central visual field, pattern-reversal visual evoked potentials (pVEP), ON-OFF and full-field electroretinogram (ERG). PRINCIPAL FINDINGS: No effect of ZK 200775 was seen on eye position or motility, stereopsis, pupillary function or central visual field testing. Visual acuity and dark vision deteriorated significantly in both treated groups. Color vision was most remarkably impaired. The dark-adapted ERG revealed a reduction of oscillatory potentials (OP) and partly of the a- and b-wave, furthermore an alteration of b-wave morphology and an insignificantly elevated b/a-ratio. Cone-ERG modalities showed decreased amplitudes and delayed implicit times. In the ON-OFF ERG the ON-answer amplitudes increased whereas the peak times of the OFF-answer were reduced. The pattern VEP exhibited lower amplitudes and prolonged peak times. CONCLUSIONS: The AMPA receptor blockade led to a strong impairment of typical OFF-pathway functions like color vision and the cone ERG. On the other hand the ON-pathway as measured by dark vision and the scotopic ERG was affected as well. This further elucidates the interdependence of both pathways. TRIAL REGISTRATION: ClinicalTrials.gov NCT00999284. |
| | |
Authors:
|
Richard Bergholz; Thomas Staks; Klaus Rüther |
Related Documents
:
|
20732319 - Nitric oxide amplifies the rat electroretinogram. 16638169 - Origin of electroretinogram amplitude growth during light adaptation in pigmented rats. 8848349 - Binaural interaction in human neonatal auditory brainstem. 21490259 - Staying the course: chemical signal spatial properties and concentration mediate cross-... 15455799 - Are circadian variations in the electroretinogram evident on routine testing? 7283319 - Retinal functions in snowflake degeneration. 16820199 - External bleaching therapy with activation by heat, light or laser--a systematic review. 1578079 - The effects of ultraviolet-a wavelengths in light therapy for seasonal depression. 19500609 - Being in the dark about your hand: resolution of visuo-proprioceptive conflict by disow... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-08-12 |
Journal Detail:
|
Title: PloS one Volume: 5 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-08-16 Completed Date: 2010-11-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States |
Other Details:
|
Languages: eng Pagination: e12111 Citation Subset: IM |
Affiliation:
|
Department of Ophthalmology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany. richard.bergholz@charite.de |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00999284 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Color Vision / drug effects, physiology Darkness Electroretinography Evoked Potentials, Visual / drug effects Humans Male Middle Aged Phosphonic Acids / pharmacology* Quinoxalines / pharmacology* Receptors, AMPA / antagonists & inhibitors* Vision, Ocular / drug effects*, physiology* Visual Acuity / drug effects, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Phosphonic Acids; 0/Quinoxalines; 0/Receptors, AMPA; 0/ZK 200775 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 A...
Next Document: Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity i...